Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.22.2.2
Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Organization And Summary Of Significant Accounting Policies [Line Items]          
Accumulated deficit $ (422,719)   $ (422,719)   $ (352,050)
Cash, cash equivalents, and marketable securities 79,400   79,400    
Restricted cash included in other assets $ 2,489 $ 3,668 $ 2,489 $ 3,668  
Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other assets Other assets Other assets Other assets  
ASU No. 2021-10          
Organization And Summary Of Significant Accounting Policies [Line Items]          
Change in Accounting Principle, Accounting Standards Update, Adopted [true false] true   true    
Change in Accounting Principle, Accounting Standards Update, Adoption Date Jan. 01, 2022   Jan. 01, 2022    
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] true   true    
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Vertex Pharmaceuticals Inc          
Organization And Summary Of Significant Accounting Policies [Line Items]          
Percentage of total revenues 0.00% 65.00% 0.00% 19.00%  
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Takeda Pharmaceuticals Inc          
Organization And Summary Of Significant Accounting Policies [Line Items]          
Percentage of total revenues 0.00% 0.00% 15.00% 63.00%  
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Bristol Myers Squibb          
Organization And Summary Of Significant Accounting Policies [Line Items]          
Percentage of total revenues 100.00% 35.00% 85.00% 18.00%